Clinical Trials Browser

Phase 2/3 × Multiple Myeloma × fludarabine × Clear all

NCT00714259 2017-07-24

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Phase 2/3 Terminated

5 enrolled 11 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell, Lymphoma, Mantle-Cell